125317-39-7
- Product Name：Vinorelbine Tartrate
- Molecular Formula：C45H54N4O8.2(C4H6O6)
- Purity：99%
- Molecular Weight：1079.11 .
Product Details:
CasNo： 125317-39-7
Molecular Formula： C45H54N4O8.2(C4H6O6)
Appearance： white to off-white crystalline powder
Factory Supply Best Quality Vinorelbine Tartrate 125317-39-7 Efficient Delivery
- Molecular Formula:C45H54N4O8.2(C4H6O6)
- Molecular Weight:1079.11 .
- Appearance/Colour:white to off-white crystalline powder
- Melting Point:181-183 °C
- Refractive Index:1.675
- PSA：363.99000
- Density:1.36 g/cm3
- LogP:0.44920
Vinorelbine tartrate(Cas 125317-39-7) Usage
|
Overview |
Vinorelbine Tartrate is a semi-synthetic vinca alkaloid administered intravenously. It is a chemotherapy medication derived from the periwinkle plant. Vinorelbine tartrate is known for its significant activity against various malignancies, including advanced non-small cell lung cancer (NSCLC) and breast cancer. However, it is important to note that it is a moderate vesicant, potentially leading to injection site reactions. |
|
Chemical properties |
White or almost white powder or crystalline powder, odorless. |
|
Application |
Antineoplastic agents |
|
Chemical Properties |
Pale Yellow Powder |
|
Uses |
Vinorelbine tartrate is indicated for the treatment of advanced non-small cell lung cancer (NSCLC) in adults. It is often used as part of combination chemotherapy regimens for the management of advanced breast cancer, particularly in patients who have failed previous treatments. In addition to NSCLC and breast cancer, vinorelbine tartrate is also used in the treatment of relapsed or refractory Hodgkin lymphoma. |
| FDA Approval | Vinorelbine tartrate, marketed under the brand name Navelbine, was approved by the U.S. Food and Drug Administration (FDA) in December 1994 for the treatment of advanced non-small cell lung cancer (NSCLC). It has since been approved for various other indications, including metastatic breast cancer. It is currently under review by the FDA for potential additional indications, such as first-line treatment of advanced NSCLC. |
|
Definition |
ChEBI: The L-(+)-tartrate salt of vinorelbine. |
InChI:InChI=1/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1
125317-39-7 Relevant articles
Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid.
Brogden JM 1 , Nevidjon B
, Oncology Nursing Forum, 01 May 1995, 22(4):635-646
To review the drug profile and nursing implications of a new vinca alkaloid, vinorelbine tartrate (Navelbine, Burroughs Wellcome Co., Research Triangle Park, NC).
Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine)
Rittenberg CN 1 , Gralla RJ , Rehmeyer TA
, Oncology Nursing Forum, 01 May 1995, 22(4):707-710
To determine the effect of duration of infusion time on venous irritation in patients receiving vinorelbine tartrate (Navelbine, Burroughs Wellcome Co., Research Triangle Park, NC) in combination with cisplatin or mitomycin.
125317-39-7 Downstream products
-
854607-08-2
11'-phenylvinorelbine
-
854606-83-0
11'-(phenylsulfanyl)vinorelbine
-
854607-32-2
11'-(4-methoxyphenylamino)-3-(tert-butyldimethylsilanyloxy)vinorelbine
-
854607-29-7
11'-benzhydrylidene-amino-3-(tert-butyldimethylsilanyloxy)vinorelbine
Relevant Products
-
Levofloxacin HemihydrateCAS：138199-71-0
-
Tenofovir Alafenamide FumarateCAS：1392275-56-7
-
Amikacin SulphateCAS：39831-55-5
